Document is current
Any future updates will be listed below
-
Authors
Puente, Javier https://orcid.org/0000-0002-6910-1331
Rodríguez-Vida, Alejo
Sevillano, Elena
Estévez, Sergio Vázquez
Fernández, Carlos Álvarez
Chirivella, Isabel
Climent, Miguel Ángel
Fernández, Ovidio
de Liaño, Alfonso Gómez
Valderrama, Begoña P.
- License Information
-
More Information
Article History
Received: 29 July 2025
Accepted: 15 August 2025
First Online: 17 September 2025
Declarations
:
: Javier Puente has received speaker fees and attended advisory boards for Astellas, MSD, Janssen, Roche, Eisai, Bayer, AstraZeneca, and Ipsen; has received grants and attended an advisory board for Merck; has received speaker fees from BMS; and has received speaker fees and grants, and attended advisory boards for Gilead and Novartis. Alejo Rodríguez-Vida has received speaker fees and attended advisory boards for Astellas, MSD, BMS, and Merck. Sergio Vázquez Estévez has received speaker fees and attended advisory boards for Astellas, BMS, Merck, MSD, and Roche. Carlos Álvarez Fernández has received speaker fees and attended advisory boards for Pfizer and Bayer; and has received speaker fees from AstraZeneca, Merck/Pfizer, BMS, and MSD. Miguel Ángel Climent has received speaker fees from AstraZeneca and BMS; has attended advisory boards for Astellas and MSD; has received speaker fees and attended an advisory board for Merck; and has received a grant from Janssen. Ovidio Fernández has attended an advisory board for Pfizer; has received speaker fees from Astellas, Bayer, BMS, AstraZeneca, MSD, and Regeneron; and has received speaker fees and attended advisory boards for Janssen, AAA-Novartis, and Pierre Fabre. Alfonso Gómez de Liaño has received non-financial support and other fees and attended advisory boards for AstraZeneca and MSD; has received speaker fees and attended an advisory board for Astellas; has received speaker fees and a grant from BMS; has received other fees from Gilead; has received speaker and other fees and attended an advisory board for Johnson & Johnson; has received non-financial support from Merck; and has received non-financial support and attended an advisory board for Roche. Begoña Pérez Valderrama has received speaker and other fees and attended advisory boards for Bristol-Myers Squibb, Pfizer, Astellas, Merck, MSD, and AstraZeneca; has received speaker fees and attended advisory boards for Bayer and AAA HealthCare; has attended advisory boards for Janssen Oncology and Recordati; has received speaker fees from Almirall Pharma; and has received other fees from Roche. Elena Sevillano and Isabel Chirivella declare that they have no conflicts of interest.
: The manuscript does not contain clinical studies or patient data.
